Sign In
30 Jun 2015 11:39
30 June 2015
Venn Life Sciences Holdings plc
Result of Annual General Meeting
The Board of Venn Life Sciences Holdings plc (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at its Annual General Meeting held earlier today, 30 June 2015, all resolutions were duly passed.
For further information:
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer Jonathan Hartshorn, Chief Financial Officer | Tel: +353 154 99 341 |
Orla McGuinness, Marketing Manager | Tel: +33 (0)1 30 82 67 07 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
Alex Davies (Institutional Sales) | Tel: 020 7533 7727 |
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
ORPH.L (ORPH)
Follow the stocks
